BioVector® BCWM.1 人类华氏巨球蛋白血症细胞系 / BCWM.1 Human Waldenström’s Macroglobulinemia Cell Line

通用定义 / General Definition:

BioVector® BCWM.1 是一种源自华氏巨球蛋白血症（Waldenström’s Macroglobulinemia, WM）患者骨髓的淋巴浆细胞样淋巴瘤细胞系。该细胞系具有典型的 $MYD88^{L265P}$ 突变，这是 WM 患者中最常见的遗传改变。作为研究 WM 病理生理学、IgM 分泌机制以及评估布鲁顿酪氨酸激酶（BTK）抑制剂等新型靶向药物的支柱模型，BioVector® BCWM.1 在血液肿瘤学研究中具有极高的应用价值。

BioVector® BCWM.1 is a lymphoplasmacytic lymphoma cell line derived from the bone marrow of a patient with Waldenström’s Macroglobulinemia (WM). The cell line features the signature $MYD88^{L265P}$ mutation, which is present in the vast majority of WM patients. As a cornerstone model for studying WM pathophysiology, IgM secretion mechanisms, and evaluating novel targeted therapies such as Bruton’s Tyrosine Kinase (BTK) inhibitors, BioVector® BCWM.1 is highly instrumental in hemato-oncology research.

BioVector® BCWM.1 细胞系技术说明书 (Cell Line Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® BCWM.1 人华氏巨球蛋白血症细胞

• 细胞来源： 人类 (Human)

• 组织来源： 骨髓 (Bone Marrow)

• 生长特性： 悬浮生长 (Suspension)

• 细胞形态： 淋巴母细胞样/浆细胞样

2. 培养条件

• 基础培养基： BioVector® RPMI 1640 培养基

• 血清添加： 10% - 20% BioVector® 胎牛血清 (FBS)（建议初始传代使用 20% 以增强活力）

• 培养环境： 37°C，5% $CO_2$，饱和湿度

3. 细胞应用

• 突变研究：$MYD88^{L265P}$ 介导的信号转导研究。

• 药物筛选： 评估 BTK 抑制剂（如伊布替尼）及其他小分子药物的疗效。

• 免疫球蛋白研究： 单克隆 IgM 分泌及 B 细胞分化机制探索。

4. 注意事项

• 生长密度： 悬浮细胞需保持在适当密度，建议维持在 $5 \times 10^5$ 至 $2 \times 10^6$ cells/mL 之间。

• 结团现象： 细胞在生长旺盛时可能出现轻微结团，属于正常生理状态，轻柔吹打即可散开。

English Datasheet

1. General Product Information

• Product Name: BioVector® BCWM.1 Human Waldenström’s Macroglobulinemia Cell Line

• Organism: Human

• Tissue Source: Bone Marrow

• Growth Properties: Suspension

• Morphology: Lymphoblast-like / Plasmacytoid

2. Culture Conditions

• Basal Medium: BioVector® RPMI 1640 Medium

• Serum Supplement: 10% - 20% BioVector® Fetal Bovine Serum (FBS) (20% is recommended for recovery and early passages)

• Incubation: 37°C, 5% $CO_2$, Saturated Humidity

3. Applications

• Mutation Studies: Research on $MYD88^{L265P}$ mediated signaling pathways.

• Drug Screening: Evaluation of BTK inhibitors (e.g., Ibrutinib) and other small molecule therapeutics.

• Immunoglobulin Research: Exploration of monoclonal IgM secretion and B-cell differentiation mechanisms.

4. Key Usage Notes

• Cell Density: Maintain suspension cultures between $5 \times 10^5$ and $2 \times 10^6$ cells/mL for optimal growth.

• Clumping: Slight cell clumping may occur during active proliferation; this is normal and can be dispersed by gentle pipetting.

Note: Handle BioVector® BCWM.1 cells under Biosafety Level 2 (BSL-2) conditions. To ensure the stability of the $MYD88$ mutation profile and high IgM secretion, the consistent use of BioVector® RPMI 1640 Medium and BioVector® Fetal Bovine Serum is highly recommended.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net